Edition:
United States

Glenmark Pharmaceuticals Ltd (GLEN.NS)

GLEN.NS on National Stock Exchange of India

875.85INR
6:16am EDT
Change (% chg)

Rs-10.70 (-1.21%)
Prev Close
Rs886.55
Open
Rs888.00
Day's High
Rs888.95
Day's Low
Rs870.30
Volume
319,104
Avg. Vol
497,632
52-wk High
Rs994.00
52-wk Low
Rs730.00

GLEN.NS

Chart for GLEN.NS

About

Glenmark Pharmaceuticals Limited is a global pharmaceutical company. The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW). It has approximately seven molecules, over two NCEs and... (more)

Overall

Beta: 0.13
Market Cap(Mil.): Rs250,156.20
Shares Outstanding(Mil.): 282.17
Dividend: 2.00
Yield (%): 0.23

Financials

  GLEN.NS Industry Sector
P/E (TTM): 24.04 29.17 29.94
EPS (TTM): 36.87 -- --
ROI: -- 13.48 13.01
ROE: -- 14.39 14.16

BRIEF-Glenmark Pharma gets ANDA approval from USFDA for clobetasol propionate ointment

* Says receives ANDA approval for clobetasol propionate ointment USP, 0.05% Source text: (http://bit.ly/2n2kRUp) Further company coverage:

Mar 20 2017

BRIEF-Glenmark Pharma gets tentative FDA nod for fingolimod capsules

* Says Glenmark Pharmaceuticals receives tentative ANDA approval for Fingolimod capsules, 0.5 mg Source text: http://bit.ly/2nciKQ2 Further company coverage:

Mar 20 2017

BRIEF-Glenmark Pharma gets FDA nod of IND for GSP 304

* Says Glenmark Pharmaceuticals receives FDA clearance of IND for GSP 304

Mar 07 2017

BRIEF-Glenmark Pharmaceuticals receives FDA clearance of IND for GSP 304

* Glenmark Pharmaceuticals receives FDA clearance of IND for GSP 304

Mar 07 2017

BRIEF-Glenmark Pharmaceuticals and Evestra sign partnership agreement for generic nuvaring

* Says Glenmark Pharmaceuticals and Evestra, Inc. announce partnership agreement for generic nuvaring

Mar 01 2017

BRIEF-Glenmark Pharmaceuticals Dec-qtr consol profit more than doubles

* Glenmark Pharmaceuticals Ltd - dec-quarter consol net profit 4.77 billion rupees

Feb 02 2017

BRIEF-Glenmark Pharmaceuticals sees revenues to grow at a CAGR of 15-20 pct over next 5 years

* Says POC study ongoing in USA and Canada in adults with moderate-to-severe ad for GBR 830; expect to complete by q3 cy17

Jan 10 2017

BRIEF-Glenmark Pharmaceuticals Sept qtr consol profit up about 11 pct

* Glenmark Pharmaceuticals - sept-quarter consol net profit 2.19 billion rupees

Oct 27 2016

BRIEF-Glenmark Pharma gets FDA nod for generic version of skin disorder drug

* Receives ANDA approval for nystatin and triamcinolone acetonide cream USP, 100,000 units/gram and 1 mg/g Source text: http://bit.ly/2faznIz Further company coverage: (Bengaluru newsroom)

Oct 24 2016

BRIEF-Glenmark appoints Kurt Stoeckli as chief scientific officer

* Glenmark appoints Kurt Stoeckli as president and chief scientific officer Source text: http://bit.ly/2e7UUlV Further company coverage:

Oct 13 2016

More From Around the Web

Earnings vs. Estimates